**Epidemiology, Transmission, Risk Factors, and International Responses of Coronavirus Disease 2019: A Comprehensive Review**

**Han Li1, Seung Won Burm2, Sung Hwi Hong2,3, Ramy Abou Ghayda3,4, Andreas Kronbichler5, Lee Smith6, Ai Koyanagi7,8, Louis Jacob7,9, Keum Hwa Lee10, Jae Il Shin10**

1. University of Florida College of Medicine, Gainesville, FL 32610, USA

2. Yonsei University College of Medicine, 03722, Seoul, Republic of Korea

3. Department of Global Health and Population, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA

4. Division of Urology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 02115, USA

5. Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck 6020, Austria

6. The Cambridge Centre for Sport and Exercise Science, Anglia Ruskin University, Cambridge, CB1 1PT, UK

7. Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, 08830 Barcelona, Spain

8. ICREA, Pg. Lluis Companys 23, 08010 Barcelona, Spain

9. Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, 78000 Versailles, France

10. Department of Pediatrics, Yonsei University College of Medicine, 03722, Seoul, Republic of Korea

**Abstract**

Coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide pandemic. The first reports of patients with COVID-19 were provided to WHO on 31 December 2019, presumably associated with seafood markets in Wuhan. As of 25 October 2020, more than 42 million cases have been confirmed worldwide, with more than 1.1 million deaths. Asymptomatic transmission contributes significantly to transmission, and clinical features are non-specific to the disease. Thus, the diagnosis of COVID-19 requires specific viral RNA testing. The disease demonstrates extensive human-to-human transmissibility and has infected healthcare workers at high rates. Clinical awareness of the epidemiology and the risk factors for nosocomial transmission of COVID-19 is essential to prevent infection. Moreover, effective control measures should be further identified by comprehensive evaluation of hospital and community responses. In this review, we provide a comprehensive update on the epidemiology, presentation, transmission, risk factors, and public health measures associated with COVID-19. We also review past insights from previous coronavirus epidemics—severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)—to suggest measures to reduce transmission.

**Keywords: Infectious disease transmission, SARS virus, Middle East respiratory syndrome coronavirus, Severe acute respiratory syndrome coronavirus 2, Coronavirus infections**

Introduction

Massive global health concern rose at the beginning of 2020, due to a new coronavirus detected in Wuhan, China.1 The first report of a cluster of patients with pneumonia from an unknown cause was provided to the World Health Organization (WHO) China Country Office on 31 Dec 2019.2 Subsequently, multiple cases of this pneumonia grew rapidly in Wuhan, which were mainly linked with exposures in seafood wholesale markets.1,3 The causative agent was isolated on 7 Jan, and its whole genome sequence analyzed.4 On 11 February 2020, WHO named the novel coronavirus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease as coronavirus disease 2019 (COVID-19).5 Despite efforts to contain the virus, infectious outbreaks spread globally from China.5 WHO designated the outbreak, which had at the time reached multiple continents outside Asia, as a pandemic on 11 March to coordinate international efforts to mitigate contagion.6

As of 25 October 2020, there have been more than 42 million confirmed cases and more than 1.1 million deaths.7 Although the novel coronavirus is being investigated worldwide, many questions lay unanswered. Here, we review the epidemiology, risk factors, and transmission of SARS-CoV-2. We seek measures for individuals, organizations, and nations to minimize risks of household, nosocomial, and local community transmission. We also investigated preventive methods to block further transmission through comparison with the Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in 2012 and severe acute respiratory syndrome coronavirus (SARS-CoV) outbreak in 2002.8

Epidemiology

Reproduction Number (R0)

Knowing the mean doubling time using the reproduction number (R0) for diseases allows the understanding of the speed and extent of transmission. Current estimates are not at consensus; the exact numbers of infected people cannot be appropriately surveyed due to asymptomatic spread, increased likelihood of detection of severe cases, and low availability of PCR test kits.9 One research team at Boston Children’s Hospital estimated R0 as between 2.0 and 3.3 by applying an Incidence Decay and Exponential Adjustment (IDEA) model.10 By fitting a deterministic Susceptible-Exposed-Infected-Recovered (SEIR) epidemiological model, a team at Lancaster University suggested R0 to be approximately 3.1.11 They assumed Poisson-distributed daily increments using daily report data in Chinese cities and in other countries. Another group of researchers at York University also used a deterministic SEIR compartmental model but proposed an R0 value of 6.47.12 A simplified version of the Bats-Hosts-Reservoir-People transmission network model—the Reservoir-People (RP) transmission network model—was created by a team at Xiamen University and calculated R0 values for each stage of transmission.13 Under this model, R0 for reservoir-to-person and person-to-person was assessed as 2.3 and 3.58, respectively. Epidemiologists in London estimated that 1.5~3.5 people were infected by each case in the early stage of the outbreak.14 Overall, low numbers of reported cases and lack of detection methods at the early stage of this crisis gave high uncertainty to modeling.9 Further studies with larger sample sizes are needed to approximate the true value.

Incubation Period

The incubation period is widely believed to be one to two weeks.15 A study published on 26 March reported a 5.2-day (95% CI, 4.1-7.0) incubation period.16 Another study reached a similar estimate of 5.1 days (95% CI, 4.5-5.8) and reported that 97.5% of symptomatic cases develop symptoms within 11.5 days (95% CI, 8.2-15.6).17 The WHO reported that patients who contract COVID-19 mostly develop signs and symptoms after 5~6 days from infection.18 Accordingly, the WHO recommends travelers returning from affected areas to self-monitor for symptoms for 14 days and to follow the national protocols of receiving countries.19 However, some outliers exist. One Japanese woman tested positive on 6 February after previously testing negative, and case number 25 in Korea confirmed positive again on 28th February, six days after discharge.20 However, it is currently unclear whether these cases suggest a dormancy period longer than 14 days, the possibility of reinfection, or sustained viral load following functional recovery. Further research on the incubation period or recurrence of the virus is needed to eliminate hidden transmission.

Non-Specific Clinical Features

Since early clinical features are not disease-specific, early diagnosis of the disease requires clinical awareness about the SARS-CoV-2 infection.21 According to two studies aggregating 100,596 cases, 80%-81% of symptomatic patients show mild symptoms, and 13.8% showed severe disease.18,22 Reported symptoms include dry cough, fever, malaise, nasal congestion, fatigue, shortness of breath, sputum production, headache, sore throat, myalgia or arthralgia, diarrhea, dyspnea, hemoptysis, anosmia, ageusia, headache, and nausea or vomiting.23-25 Anosmia and ageusia specifically occur in 47%-88% of mild to moderate COVID-19 cases and often co-occur.26,27 Females are more likely to have anosmia and ageusia with COVID-19. The limited data available suggest that such dysfunction is self-resolving within 14 days after disease recovery, with over half recovering from anosmia in the first eight days.27 In early cases reported in Wuhan, severe acute respiratory infection symptoms were shown, and some patients rapidly developed acute respiratory distress syndrome (ARDS) and other serious complications.25

Comparison to SARS and MERS

SARS and COVID-19 share similar transmission routes, risk factors, and disease progression. The SARS epidemic reported 8,098 cases with 774 deaths and was controlled within eight months.28 Twenty-six countries experienced infections, but most cases were concentrated in China, Taiwan, Hong Kong, Singapore, and Canada. SARS is only transmissible by symptomatic patients, with viral load peaking 6-11 days after onset of illness.29 However, COVID-19 differs from SARS in three characteristics: asymptomatic transmission, a well-connected initial outbreak site, and strain on public health resources. With SARS, the co-occurrence of symptoms with viral shedding allowed for a sensitive case definition and isolation of high-risk patients.28 The household secondary attack rate for SARS was 6.2% in Singapore and 10% in Toronto, compared to a 30% secondary attack rate for COVID-19 by some higher estimates.30-32 Compared to COVID-19, SARS has both a longer time to peak viral load from onset and a shorter incubation period, explaining the decreased likelihood of asymptomatic transmission in SARS.33,34 The R0 of SARS general transmission ranges from 0.58-1.17, partially due to isolation control measures35. Three out of 5 super spreading events in Singapore were possible largely because of atypical case presentations. Two additional super spreading events were propagated by inadequate plumbing or ventilation, instead of the failure to detect infected cases.35-38 In contrast, the asymptomatic transmission of COVID-19 led to increased community and household transmission. In February, Liu et al. documented 8 COVID-19 super spreading events in China through restaurants.39 Difficulty tracing asymptomatic carriers, combined with high international traffic through Wuhan, allowed community transmission and made tracing patients more difficult. The resulting demand on hospital resources impaired quarantining efforts on hospital staff and the existence of asymptomatic carriers lessened the effectiveness of patient isolation.

The 2012 MERS epidemic infected 2,553 people as of March 2020 with 876 associated deaths.40 MERS also shares a similar disease course, transmission routes, and risk factors with SARS and COVID-19.40 Like COVID-19, MERS has been transmitted by asymptomatic carriers.41 However, the virus requires prolonged exposure before transmission other humans and is primarily spread sporadically by animal-to-human transmission, decreasing the likelihood of a large-scale outbreak.42 For example, the peak viral load occurs 7 days after onset in cases without needing supplemental oxygen and 14-21 days in cases delivered oxygen, in contrast to the 3-day peak viral load in COVID-19.34 However, the incubation of MERS, 4.5-7.8 days, is more similar to SARS than COVID-19. The estimates secondary attack rate for MERS range from 0.42%-15.8%.43 In one study by Drosten et al., only 14 out of 280 secondary household contacts of 26 index patients tested positive by antibody tests or reverse transcription polymerase chain reaction (RT-PCR).44 Nosocomial transmission accounts for a significant portion of human-to-human transmission: 18.6% of MERS cases comprise healthcare workers (HCW).45 The R0 for general transmission ranges from <1 to 3,11 but the R0 specific for nosocomial transmission is estimated to be between 1.9 and 4.04.46 Table 1 summarizes the comparisons between SARS, MERS, and COVID-19.

Person to Person Transmission

Nosocomial transmission of SARS, MERS, and COVID-19

The previous 2003 SARS outbreak led to over 966 infections in health care staff.47 The low minimum distance between beds, previously performing resuscitation in the ward, low availability of washing facilities for staff, staff working while sick, and using ventilation or oxygen therapy have been associated with SARS nosocomial transmission.48 Effective strategies against nosocomial transmission were to isolate known carriers, ban hospital visitors, and close infected wards.49 Patients with fever or respiratory distress in sites of the outbreak were isolated until SARS was ruled out.28 If the patient index could be identified before the estimated second incubation period, HCWs in contact with the patient were quarantined. If the patient index could not be identified, entire hospitals were closed.49 Some ICUs were entirely converted to negative pressure airflow, with hot, warm, and cold zones that necessitated full airborne precautions, droplet precautions, and no personal protective equipment (PPE), respectively.50 In Toronto, the transmission was primarily nosocomial.51 Enactment of hospital control, including droplet PPE and negative airflow isolation, 20 days after the first SARS death, reduced the number of cases to 0 for 20 consecutive days. However, subsequent relaxation of hospital control led to a resurgence of infection.51

With MERS, a sensitive case definition was critical to identify sources of and eliminate transmission.46 In Thailand, the nosocomial transmission was avoided entirely from three index cases by directing all patients with acute respiratory illness traveling from countries with MERS outbreaks to designated entrances and airborne isolation rooms until MERS could be ruled out.52 HCWs were required to adopt droplet precautions when working with suspected patients, as per the Centers for Disease Control and Prevention (CDC) guidelines. In the United States, HCWs exposed to suspected cases were required to undergo home quarantine for 14 days and test negative before returning to work.53 Compared to COVID-19, MERS is a more fatal condition that may also spread before confirmatory diagnosis,41 and its nosocomial transmission was controlled by similar early identification, isolation, and PPE guidelines as with SARS.

By 11 February 2020, 1,716 health staff in China were confirmed SARS-CoV-2 positive.54 In a cohort of 138 patients, Wang et al. estimated that 41% were infected by nosocomial transmission.55 WHO recommends droplet and contact precautions for patients suspected of COVID-19 and airborne precautions while performing aerosol-generating procedures (intubation, cardiac resuscitation, high-flow nasal cannula, bronchoscopy), though some recommend airborne precautions in all cases.56 Insights from the SARS outbreak have been used to create a number of recommendations for controlling COVID-19, which are summarized in Table 2. In short, it is recommended to place symptomatic hospital staff under self-quarantine, equip patients with N95 masks, and inform receiving hospitals of suspected infectious arrivals beforehand.54,57 Patients with cough, dyspnea, and fever should be isolated in daily-disinfected, single negative pressure rooms until tested negative for COVID-19. Airborne precautions, including N95 respirator masks, gown, double-layered gloves, coverall, and protective shoes, were also recommended.57 Patients with mild symptoms may be sent for home care, but with the stipulations that home isolation necessitates careful prior assessment and that patients who do not recover should immediately seek further treatment.57

An elevated risk of hospital transmission has been described subsequent to treating critically-ill patients.50,58,59 For the critically ill, it is recommended to adopt airborne precautions. Additional critical care measures include equipping patients with masks during high flow nasal cannula treatments, using ventilators with filters and heat-moisture exchangers, and using masks during bronchoscopy.59 When possible, rapid intubation techniques should be utilized, bag-mask ventilation should be avoided, and early planned intubations should be prioritized rather than emergency intubations.50,60 For prolonged procedures, powered air-purifying respirators (PAPR) may be an alternative to N95 masks, but no trials have demonstrated improved or equivalent risk-reduction compared to the N95.50 One group described an increased risk of transmission with pulmonary function tests and recommended, in addition to isolation and disinfection procedures, suspending tests for suspected COVID-19 cases and for patients without an immediate need.61 Oxygen therapy can disperse particles in varying patterns depending on the devices used. Continuous positive airway pressure (CPAP) via an oronasal mask and non-invasive ventilation (NIV) via air-cushioned helmet show minimum room contamination among nasal cannula, oronasal mask, Venturi mask, non-rebreathing mask, CPAP via an oronasal mask, CPAP via nasal pillows, high flow nasal cannula, NIV via full face mask, NIV via helmet without tight air cushion, and NIV via helmet with tight air cushion.60

Transmission by Asymptomatic Individuals

Asymptomatic and presymptomatic transmission of COVID-19 have been documented. Studies in January 2020 were among the first to show the possibility of asymptomatic transmission by demonstrating mild or asymptomatic cases in an estimated 80% of patients, as well as asymptomatic infection of a child.22,23 On 6 March, Luo et al. traced three SARS-CoV-2 infections from patients who otherwise had no contact with Wuhan or animals to asymptomatic carrier sources.62 Asymptomatic transmission was also demonstrated by a Wuhan resident to 5 family members and by clusters of patients in Singapore.63, 64 Asymptomatic infection is consistent with the longer incubation period, shorter time to peak viral load, and shorter serial interval of COVID-19. Nishiura and colleagues estimated the serial interval by following 28 infector-infected pairs as 4.6 days (95% CI, 3.5-5.9), shorter than many incubation period estimates, suggesting transmission during subclinical infection.65

Presymptomatic and asymptomatic infection are expected to contribute significantly to COVID-19 transmission. On 13 March, Nishiura and colleagues used data from 565 Japanese citizens to estimate the proportion of asymptomatic infections as 30.8%.66 Since antibody testing was developed, a Stanford group in Santa Clara County recruited 3,330 people used lateral flow immunoassays to estimate the population-weighted seroprevalence of antibodies to SARS-CoV-2 as 2.49% (95 CI 1.80%-3.17%) to 4.16% (95% CI, 2.58%-5.70%).67 Another group in a northern Iran province used a cohort of 528 people to estimate the population antibody seropositivity prevalence as 33% (95% CI, 28-39%). Of the sample, 65 subjects (18%) had no symptoms but had antibodies to SARS-CoV-2.68 Contact tracing of 100 patients revealed similar secondary attack rates between presymptomatic and symptomatic exposures.69 Byambasuren et al. recently found in a meta-analysis of 663 positive cases that 17% were asymptomatic, with a 42% lower relative risk of asymptomatic transmission.70 It is estimated that up to 62% of transmission occurs presymptomatically, with true asymptomatic transmission being uncommon.71

Severity of Illness and Transmission

Preliminary evidence from epidemiological and biological studies have suggested both increased and prolonged viral transmission associated with severe illness. Reports have identified an increased risk of contracting the disease for HCWs who care for or resuscitate critically ill people with COVID-19.50,59 The median duration of viral shedding for severely ill patients was calculated as 31 days from illness onset by one study, higher than the estimations of median viral shedding duration (17 days) for the collective population.72,73 In a cohort of 113 patients, severe illness, emergent treatments (corticosteroid therapy and mechanical ventilation), and delayed recovery were associated with longer viral shedding times.72 A separate cohort of 32 ICU and non-ICU patients with COVID-19 demonstrated a viral shedding time about seven days longer in the ICU group.74 However, He et al. found no differences in either viral load or shedding time between 94 mild and severe patients.75 Given ambiguous findings relating severity to increased transmission, it is currently unclear whether the apparent increased infection rates from patients who are critically ill intrinsically result from elevated viral load or are generated from aerosol-generating emergent techniques.

Risk Factors

Demographics & Comorbid Conditions

The most well-documented demographic risk factor for infection and morbidity is old age. In two household transmission studies, secondary contacts above 60 demonstrated increased secondary attack rates by 25%-57% compared to the general population.76 Out of 799 patients, Chen and colleagues described that patients who died were older on average than those who survived.77 Male sex, obesity, and smoking also associate with mortality, though it is difficult to quantify the relative risks due to possible confounding and limited sample size.78

Novel comorbidities associated with poor COVID-19 outcomes are continuously being described. Among those discovered early, hypertension occurs most frequently with infection and has been validated across multiple studies as a risk factor for mortality.79,80 Respiratory disease, cardiovascular disease, diabetes, kidney disease, and cancer have also been linked to increased risk of death.79,80 In some studies, coagulopathies and inflammation appear to be linked to severe outcomes or death. In a cohort study of 201 patients, neutrophilia, higher lactate dehydrogenase, and D-dimer were associated with the development of ARDS and death.81 The inflammatory biomarkers procalcitonin, interleukin-6, tumor necrosis factor alpha, and neutrophil to lymphocyte ratio are also risk factors for fatal outcomes.82 In a meta-analysis of 9 studies, Lippi et al. linked thrombocytopenia with COVID-19 severity and mortality.83 Kidney disease and markers of abnormal kidney function are also associated with death in COVID-19.84 Although further work is necessary to confirm current prognostic markers for vulnerability to COVID-19, it seems likely that poor cardiovascular and respiratory function predispose people to adverse outcomes.

Environmental Factors

SARS-CoV-2 environmental risk factors comprise surface contamination, fecal-oral transmission, and airborne transmission.85,86 In an experimental study aerosolizing SARS-CoV-2-WA1-2020 viral particles, SARS-CoV-2 remained viable on plastic and stainless steel for up to 72 hours.87 In some hospital wards in China, the virus was detected on floors, computer mice, trash cans, and on handrails.88 SARS-CoV-2 has been detected in feces during and after symptomatic infection.86 Routine disinfection has been shown to reduce contamination: none of the surfaces or sewage disinfection pools in wards with SARS-CoV-2 patients were positive for SARS-CoV-2 RNA when daily chlorine-containing disinfection was followed.89

WHO guidelines encouraging social distancing of at least 2 meters are based on early evidence suggesting that COVID-19 is primarily spread by large droplets (above 5 µm), which generally fall to surfaces before traveling 2 meters.85,88 However, there exists some evidence that SARS-CoV-2 distributes widely by aerosol and beyond 2 meters by droplets. SARS-CoV-2 has been detected in the air 3 hours following manual aerosolization and in the air up to 4 meters from COVID-19 patient rooms.87,88 Aerosolized viral RNA has been detected in protective apparel removal rooms, suggesting resuspension of viral particles, and in crowded public spaces.90 A systematic review of 10 studies by Bahl and colleagues showed that eight studies suggested that droplets travel above a 2-meter distance when coughing or sneezing.56 However, Liu et al. found negligible viral air contamination in hospitals with negative ventilation and chlorine-containing disinfection, suggesting the effectiveness of proper sanitation.90

Controlling Measures

Diagnostic Testing

It is known from previous MERS and SARS outbreaks that early detection of infection is critical for blocking further transmission.52,91 Genome sequencing of SARS-CoV-2 enabled the rapid development of screening methods. Clinical testing for COVID-19 comprises either RT-PCR, the more widely used, or antibody-based tests. Currently, a majority of world-wide cases are confirmed through nucleic acid laboratory tests.

Early eligibility criteria typically required an epidemiological link, the onset of symptoms, and negative ruling for other respiratory diseases in many countries. HCWs or those vulnerable to severe infection were eligible for testing after initial signs of fever or respiratory illness. By 20 February, only China, Taiwan, Vietnam, the Philippines, Oman, Turkey, Colombia, Gabon, and Rwanda offered testing to anyone with symptoms, and only South Korea provided asymptomatic testing,92 A large majority had no testing policy. By 2 March, a majority of nations had developed testing policies, though many nations' criteria necessitated the patient to demonstrate an epidemiological or vulnerability status. Some regions, including Singapore, northern Italy, and South Korea, effectively employed liberal testing eligibility criteria, in which any citizen with a physician's recommendation (Singapore) or with personal concern (South Korea, northern Italy) could receive testing. On 29 April, 20 nations offered testing to all people, 43 offered testing to all those who showed symptoms, and 48 offered testing only to vulnerable populations or those with epidemiological links after showing symptoms.92

Testing capacity has increased over time, with more accurate laboratory equipment and test kit supply production. By 21 April, hotspots like Italy, New Zealand, Denmark, Canada, the US, and South Korea cumulatively conducted 23.98, 19.66, 17.36, 14.99, 12.65, 12.08, and 11.14 tests per 1,000 people respectively. Thirty-five nations offered 0-5 tests per 1,000 people; 13 nations offered 5-10 tests per 1,000 people;93 and 27 nations offered above 10 tests per 1,000 people. The mean number of tests per 1,000 conducted by all nations was 11.45. If the virus continues to spread on a global level, it will be increasingly important to scale the production of accurate tests to match diagnostic demand.

Lockdown and Movement Restriction

The number of countries enforcing stay-at-home measures or gathering restrictions are summarized in Figure 1, and effective lockdown measures are shown in Table 3. From 10 February to 1 March, fewer than 15 countries combined imposed either stay-at-home measures or gathering restrictions.94 By 10 March, 21 countries restricted gatherings, and 18 countries enforced stay-at-home measures. Thirty-five recommended or required the closing of public schools. By 1 April, 131 countries restricted gatherings, of which 79 countries restricted gatherings below 10 people. On the same date, 196 countries enforced stay-at-home measures, with 70 enforcing home quarantine except for grocery shopping, exercise, and "daily trips" By 30 April, 83 countries restricted all gatherings, and 79 countries allowed home excursions only for essential trips (Figure 1). Sixteen countries limited home excursions, including essential trips, to once every few days for each household (minimal exceptions). Large-scale screening and training programs in COVID-19 recognition and isolation were also established by both hospitals and WHO.95,96

Precautions against SARS nosocomial transmission encompassed lockdown measures similar to those of the COVID-19 pandemic. In Beijing, local police, community health workers, and volunteers coordinated quarantining efforts.91 Beijing closed all public entertainment sites on 24 April 2003, within 2 months of the initial importation of the virus. All schools, except universities, were closed. Restaurants and businesses were not closed but screened for fever at entry. Travel advisories and screenings were implemented in multiple locations instead of travel bans.28,97 Singapore utilized widespread temperature testing and encouraged its citizens to check for fever several times per day.28

By 30 April, 122 countries closed educational institutions, including universities. The efficacy of school closures in reducing transmission is based on previous influenza outbreaks and is expected to be highest if the reproductive number is <2, if closures are implemented early, and if attack rates are higher in children.98 The attack rate in children for influenza is 15.2% (95% CI: 11.4%-18.9%). However, the attack rate of COVID-19 in children has been estimated as only 7.2% (95% CI: 3.0%-14.3%) and 3.8% (95% CI: 0.8%-10.6%) in males and females, respectively.99,100 A systematic review by Viner and colleagues found little evidence that school closures during the SARS and COVID-19 epidemics contributed significantly to curbing transmission, as transmission rates in schools were already low.98 One modeling study using the UK population estimated that school closures in the COVID-19 epidemic only reduced transmission by 2-4%.

Conclusion

As of 26 May 2020, more than 5 million cases and 300,000 deaths associated with COVID-19 have been recorded worldwide. SARS-CoV-2 likely to have resulted from bat-to-human transmission, and the virus demonstrates high human-to-human transmission across households, hospitals, and communities. A major proportion of cases are asymptomatic, and it is likely that asymptomatic transmission contributes significantly to transmission. Efforts curbing transmission primarily comprise 1) early identification, either through targeted or indiscriminate testing 2) lockdown and patient isolation. Previous lessons from SARS and MERS to reduce nosocomial and community transmission, such as isolating patients with respiratory illness, placing infected HCWs under quarantine, creating designated spatial pathways for suspected patients, and enabling the rapid development of testing, have been and should continue to be implemented. Novel studies describing methods to minimize aerosol generation during common hospital procedures can also be implemented to curb transmission. Disinfection, precautionary social distancing beyond the recommended 2 meters, and hand hygiene are valuable measures to prevent environmental spread of the virus.

**Table 1. Characteristics of SARS, MERS, and COVID-19 transmission**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **SARS** | **MERS** | **COVID-19** |
| **Asymptomatic transmission** | N33,34 | Y41 | Y22,23 |
| **Peak viral load after onset** | 6-11 days29 | 7 days (mild)  14-21 days34 | 3 days34 |
| **Secondary attack rate** | 6.2%-10%30-32 | 0.42%-15.8%43 | Up to 30%30-32 |
| **Primary mode of transmission** | Human-to-human | Animal-to-human42 | Human-to-human |
| **R0 (general transmission)** | 0.58-1.1735 | <1-311,46 | 1.5-6.4712,14 |
| **Incubation period** | 3.6-4.4 days33,34 | 4.5-7.8 days43 | 5.1-11.5 days17 |

Prominent characteristics of SARS, MERS, and COVID-19 are aggregated. Numerical values for secondary attack rate, R0, etc. were retrieved as ranges of the lowest and highest estimations described in each respective reference.

Abbreviations: **COVID-19 Coronavirus disease 2019; SARS Severe acute respiratory syndrome; MERS Middle East respiratory syndrome; R0 Reproduction number;**

**Table 2. Effective Measures Against Nosocomial Transmission for COVID-19 and SARS**

|  |
| --- |
| **COVID-19** |
| * Rapid isolation of HCWs, patients, and wards suspected of contacting infection56 * Daily chlorine-containing disinfection89 * PPE consisting of N95 respirator, gown, double-layered gloves, coverall, shoe covers46 * Separation of patient and HCW entrances and exits58 * Limiting patients per room58 * Equipping patients with masks46 * Adopting oxygen administration techniques that minimize droplet spread56 * Adopting airborne precautions for aerosol-generating procedures46,52 |
| **SARS** |
| * Rapid isolation of HCWs, patients, and wards suspected of contacting infection26 * Construction of SARS-specific hospitals45 * Banning hospital visitors45 * Spacing patient beds44 * Conversion of ICUs to negative-pressure environments, with hot zones, warm zones, and cold zones46 |

Measures against nosocomial transmission described to be effective are aggregated for SARS and COVID-19. Measures against MERS nosocomial transmission were similar to SARS in the articles evaluated and were not included to avoid redundancy.

Abbreviations: COVID-19 Coronavirus disease 2019; HCW Healthcare worker; SARS Severe acute respiratory syndrome; ED Emergency department; ICU Intensive care unit

**Table 3. Effective Lockdown and Quarantine Measures for COVID-19 and SARS**

|  |  |  |
| --- | --- | --- |
| **COVID-19** | | |
| *Screening* | *Gathering Restriction* | *Mobility Restriction* |
| * Monitoring confirmed cases19 * Using widely available testing92 * Development of clinical referral systems for suspected cases96 * Global education resources for screening and control96 | * Restricting gathering sizes94 * Closing public schools96 * Limiting the maximum number of people per room95 | * Administering early travel bans from infection hotspots95 * Limiting trips outside the household94 * Screening for infection at airport entry |
| **SARS** | | |
| *Screening* | *Gathering Restriction* | *Mobility Restriction* |
| * Using thermometers for temperature screening97 * Monitoring confirmed cases28 * Using community volunteers to coordinate quarantine91 * Development of clinical referral systems for suspected cases | * Closing public schools97 * Restricting gathering sizes97 | * Administering travel advisories on infection hotspots28 * Screening for infection at airport entry97 |

Measures for lockdown and quarantine described as effective against COVID-19 and SARS are aggregated. Community lockdown measures against MERS were unable to be found and thus not included.

**Abbreviations:** COVID-19 Coronavirus disease 2019; SARS Severe acute respiratory syndrome

**REFERENCES**

1. WHO. Pneumonia of unknown cause – China (5 January 2020) [accessed 2 May 2020]. Available at: https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/.

2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33.

3. WHO. Novel Coronavirus - China. 2020 [accessed 2 May 2020]. Available at: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/.

4. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470-3.

5. WHO. Novel coronavirus (2019-nCoV): situation report-22. 2020 [accessed 2 May 2020]. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1\_2.

6. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed 2020;91(1):157-160.

7. WHO. COVID-19 Weekly Epidemiological Update. 2020 [accessed 25 October 2020]. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update---27-october-2020.

8. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14:523-34.

9. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection 2020;48:155-63.

10. Majumder M, Mandl KD. Early Transmissibility Assessment of a Novel Coronavirus in Wuhan, China. SSRN Electron J 2020 doi:10.2139/ssrn.3524675.

11. Read JM, Bridgen JRE, Cummings DAT, Ho A, Jewell CP. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions. MedRxiv doi:10.1101/2020.01.23.20018549. [In press].

12. Tang B, Wang X, Li Q, Bragazzi NL, Tang S, Xiao Y, et al. Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions. J Clin Med 2020;9:462.

13. Chen T-M, Rui J, Wang Q-P, Zhao Z-Y, Cui J-A, Yin L. A mathematical model for simulating the phase-based transmissibility of a novel coronavirus. Infect Dis Poverty 2020;9.

14. Imperial College L. Report 6: Relative sensitivity of international surveillance. 2020. doi: 10.25561/77168. Accessed 20 May 2020.

15. Cimolai N. More data are required for incubation period, infectivity, and quarantine duration for COVID-19. Travel Med Infect Dis 2020:101713. doi:10.1126/science.abb1256.

16. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med 2020;382:1199-207.

17. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020;172:577-82. doi:10.7326/M20-0504.

18. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (2/28) (16-24 Feb). 2020 [accessed 2 May 2020]. Available at: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.

19. WHO. Updated WHO recommendations for international traffic in relation to COVID-19 outbreak. 2020 [accessed 2 May 2020]. Available at : https://www.who.int/ith/2019-nCoV\_advice\_for\_international\_traffic-rev/en/.

20. Yun-Kyung S. [Woman in her 70s re-confirmed after 6 days of discharge ... “Estimated recurrence in immunity deterioration”]. 2020 [accessed 2 May 2020]. Available at: http://news.khan.co.kr/kh\_news/khan\_art\_view.html?artid=202002291538001&code=940100#csidxdd591b076f439be83e678c970e39d21.

21. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

22. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41(2):145-151.

23. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514-23.

24. Moein ST, Hashemian SMR, Mansourafshar B, Khorram‐Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID‐19. Int Forum Allergy Rhinol 2020; doi:10.1002/alr.22587.

25. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.

26. Carrillo-Larco RM, Altez-Fernandez C. Anosmia and dysgeusia in COVID-19: A systematic review. Wellcome Open Res. 2020;13;5:94.

27. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251-2261.

28. Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infect Dis 2020;20:e102-e7.

29. Cheng PKC, Wong DA, Tong LKL, Ip S-M, Lo ACT, Lau C-S, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet 2004;363:1699-700.

30. Gumel AB, Ruan S, Day T, Watmough J, Brauer F, van den Driessche P, et al. Modelling strategies for controlling SARS outbreaks. Proc Biol Sci 2004;271:2223-32.

31. Wang Z, Ma W, Zheng X, Wu G, Zhang R. Household transmission of SARS-CoV-2. J Infect 2020; doi:10.1016/j.jinf.2020.03.040.

32. Wilson-Clark SD, Deeks SL, Gournis E, Hay K, Bondy S, Kennedy E, et al. Household transmission of SARS, 2003. CMAJ 2006;175:1219-23.

33. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291-300.

34. Al-Tawfiq JA. Viral loads of SARS-CoV, MERS-CoV and SARS-CoV-2 in respiratory specimens: what have we learned?. Travel Med Infect Dis. 2020;34:101629.

35. Chowell G, Castillo-Chavez C, Fenimore PW, Kribs-Zaleta CM, Arriola L, Hyman JM. Model parameters and outbreak control for SARS. Emerg Infect Dis. 2004;10(7):1258-1263.

36. Shen Z, Ning F, Zhou W, He X, Lin C, Chin DP, et al. Superspreading SARS events, Beijing, 2003. Emerg Infect Dis 2004;10:256-60.

37. Stein RA. Super-spreaders in infectious diseases. Int J of Infect Dis 2011;15:e510-e3.

38. Tomlinson B, Cockram C. SARS: experience at Prince of Wales Hospital, Hong Kong. Lancet 2003;361:1486-7.

39. Liu Y, Eggo RM, Kucharski AJ. Secondary attack rate and superspreading events for SARS-CoV-2. Lancet 2020;395:e47.

40. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) - Saudi Arabia. 2020 [accessed 25 May 2020]. Available at: https://www.who.int/csr/don/05-may-2020-mers-saudi-arabia/en/. Accessed 25 May 2020.

41. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J of Epidemiol 2020;dyaa033. doi:10.1093/ije/dyaa033. [Epub ahead of print].

42. Hemida MG, Al-Naeem A, Perera RAPM, Chin AWH, Poon LLM, Peiris M. Lack of Middle East Respiratory Syndrome Coronavirus Transmission from Infected Camels. Emerg Infect Dis 2015;21:699-701.

43. Park JE, Jung S, Kim A, Park JE. MERS transmission and risk factors: a systematic review. BMC Public Health. 2018;18(1):574.

44. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri M, Hossain R, et al. Transmission of MERS-Coronavirus in Household Contacts. N Engl J Med 2014;371:828-35.

45. Kim KM, Ki M, Cho SI, Sung M, Hong JK, Cheong HK, et al. Epidemiologic features of the first MERS outbreak in Korea: focus on Pyeongtaek St. Mary's Hospital. Epidemiol Health 2015;37:e2015041.

46. Choi S, Jung E, Choi BY, Hur YJ, Ki M. High reproduction number of Middle East respiratory syndrome coronavirus in nosocomial outbreaks: mathematical modelling in Saudi Arabia and South Korea. J of Hosp Infect 2018;99:162-8.

47. Chen WQ, Ling WH, Lu CY, Hao YT, Lin ZN, Ling L, et al. Which preventive measures might protect health care workers from SARS? BMC Public Health 2009;9:81.

48. Hui DS. Severe acute respiratory syndrome (SARS): lessons learnt in Hong Kong. J Thorac Dis 2013;5 Suppl 2:S122-6.

49. Gopalakrishna G, Choo P, Leo YS, Tay BK, Lim YT, Khan AS, et al. SARS Transmission and Hospital Containment. Emerg Infect Dis 2004;10:395-400.

50. Wax RS, Christian MD. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anesth 2020;67:568-76.

51. Svoboda T, Henry B, Shulman L, Kennedy E, Rea E, Ng W, et al. Public Health Measures to Control the Spread of the Severe Acute Respiratory Syndrome during the Outbreak in Toronto. N Engl J Med 2004;350:2352-61.

52. Wiboonchutikul S, Manosuthi W, Sangsajja C. Zero Transmission of Middle East Respiratory Syndrome: Lessons Learned From Thailand. Clin Infect Dis 2017;64:S167-S70.

53. Bialek SR, Allen D, Alvarado-Ramy F, Arthur R, Balajee A, Bell D, et al. First confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in the United States, updated information on the epidemiology of MERS-CoV infection, and guidance for the public, clinicians, and public health authorities - May 2014. MMWR Morb Mortal Wkly Rep 2014;63:431-6.

54. Zhou P, Huang Z, Xiao Y, Huang X, Fan X-G. Protecting Chinese healthcare workers while combating the 2019 novel coronavirus. Infect Control Hosp Epidemiol 2020:1-. doi:10.1017/ice.2020.60.

55. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA 2020;323:1061.

56. Bahl P, Doolan C, de Silva C, Chughtai AA, Bourouiba L, MacIntyre CR. Airborne or Droplet Precautions for Health Workers Treating Coronavirus Disease 2019? The J Infect Dis 2020;jiaa189. doi:10.1093/infdis/jiaa189.

57. Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, Fan Y-P, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7.

58. Ong J, Cross GB, Dan YY. Prevention of nosocomial SARS-CoV-2 transmission in endoscopy: international recommendations and the need for a gold standard. Gut 2020:gutjnl-2020-321154.

59. Respiratory Care Committee of Chinese Thoracic S. [Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia]. Zhonghua Jie He He hu Xi Za Zhi. 2020;17(0):E020. doi:10.3760/cma.j.issn.1001-0939.2020.0020. [Epub ahead of print].

60. Ferioli M, Cisternino C, Leo V, Pisani L, Palange P, Nava S. Protecting healthcare workers from SARS-CoV-2 infection: practical indications. Eur Respir Rev 2020;29:200068.

61. Task Force of Pulmonary Function Testing and Clinical Respiratory Physiology, Chinese Association of Chest Physicians; Pulmonary Function Testing Group, Respiratory Therapeutics Group, Chinese Thoracic Society. [Expert consensus on Pulmonary Function Testing during the epidemic of Coronavirus Disease 2019]. Zhonghua Jie He He Hu Xi Za Zhi 2020;43(4):302-307.

62. Luo S-H, Liu W, Liu Z-J, Zheng X-Y, Hong C-X, Liu Z-R, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus. Chin Med J (Engl) 2020;133:1123-5.

63. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406-1407.

64. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):411-415.

65. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (2019-nCoV) infections. Int J Infect Dis 2020;93:284-286.

66. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S-m, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J of Infect Dis 2020;94:154-5.

67. Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. MedRxiv 2020; doi:10.1101/2020.04.14.20062463. [In press].

68. Shakiba M, Hashemi Nazari SS, Mehrabian F, Rezvani SM, Ghasempour Z, Heidarzadeh A. Seroprevalence of COVID-19 virus infection in Guilan province, Iran. MedRxiv 2020; doi:10.1101/2020.04.26.20079244. [In press].

69. Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020;180(9):1156-1163.

70. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the extent of true asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. MedRxiv. 2020. doi:10.1101/2020.05.10.20097543. [Epub ahead in print].

71. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020 25;324(8):782-793.

72. Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis 2020;ciaa351. doi:10.1093/cid/ciaa351. [Epub ahead of print].

73. Zhou B, She J, Wang Y, Ma X. The duration of viral shedding of discharged patients with severe COVID-19. Clin Infect Dis 2020;ciaa451. doi:10.1093/cid/ciaa451. [Epub ahead of print].

74. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;581(7809):465-469. doi:10.1038/s41586-020-2196-x.

75. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020;26(5):672-675. doi:10.1038/s41591-020-0869-5.

76. Cheng H-Y, Jian S-W, Liu D-P, Ng T-C, Huang W-T, Lin H-H, et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. JAMA Intern Med 2020;e202020. doi:10.1001/jamainternmed.2020.2020. [Epub ahead of print].

77. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020:m1091. doi:10.1136/bmj.m1091.

78. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ 2020:m1198. doi:10.1136/bmj.m1198.

79. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91-5.

80. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239.

81. Wu C, Chen X, Cai Y, Xia Ja, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020;e200994. doi:10.1001/jamainternmed.2020.0994. [Epub ahead of print].

82. Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest 2020;S0012-3692(20)30710-8. doi:10.1016/j.chest.2020.04.010. [Epub ahead of print].

83. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020;506:145-8.

84. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97:829-38. doi:10.1016/j.kint.2020.03.005.

85. Morawska L, Cao J. Airborne transmission of SARS-CoV-2: The world should face the reality. Environ Int 2020;139:105730.

86. Jiang X, Luo M, Zou Z, Wang X, Chen C, Qiu J. Asymptomatic SARS‐CoV‐2 infected case with viral detection positive in stool but negative in nasopharyngeal samples lasts for 42 days. J Med Virol 2020;10.1002/jmv.25941. doi:10.1002/jmv.25941. [Epub ahead of print].

87. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020;382:1564-7.

88. Guo Z-D, Wang Z-Y, Zhang S-F, Li X, Li L, Li C, et al. Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. Emerg Infect Dis 2020;26.

89. Wang J, Feng H, Zhang S, Ni Z, Ni L, Chen Y, et al. SARS-CoV-2 RNA detection of hospital isolation wards hygiene monitoring during the Coronavirus Disease 2019 outbreak in a Chinese hospital. Int J Infect Dis 2020;94:103-6.

90. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature 2020. doi:10.1038/s41586-020-2271-3. [Epub ahead of print].

91. Pang X. Evaluation of Control Measures Implemented in the Severe Acute Respiratory Syndrome Outbreak in Beijing, 2003. JAMA 2003;290:3215.

92. Our World in Data. COVID-19 Testing Policies. Global Change Data Lab 2020 [accessed 8 May 2020]. Available at: https://ourworldindata.org/grapher/covid-19-testing-policy?year=2020-04-29.

93. Our World in Data. Total COVID-19 tests per 1,000 people. Global Change Data Lab. 2020 [accessed 8 May 2020]. Available at: https://ourworldindata.org/grapher/full-list-cumulative-total-tests-per-thousand?tab=map&year=2020-04-21.

94. Blavatnik School of Government UoO. Oxford COVID-19 Government Response Tracker (OxCGRT). COVID-19 Pandemic. 2020 [accessed 8 May 2020]. Available at: https://data.humdata.org/dataset/oxford-covid-19-government-response-tracker.

95. Wang L, Chen H, Qiu S, Song H. Evaluation of control measures for COVID-19 in Wuhan, China. J Infect. 2020;81(2):318-356.

96. WHO. COVID-19 Weekly Operational Update. 2020 [accessed 30 October 2020]. Available at: https://www.who.int/publications/m/item/weekly-operational-update---30-october-2020.

97. Bell DM. Public health interventions and SARS spread, 2003. Emerg Infect Dis. 2004;10(11):1900-1906.

98. Viner RM, Russell SJ, Croker H, Packer J, Ward J, Stansfield C, et al. School closure and management practices during coronavirus outbreaks including COVID-19: a rapid systematic review. Lancet Child & Adolesc Health. 2020;4:397-404.

99. Jayasundara K, Soobiah C, Thommes E, Tricco AC, Chit A. Natural attack rate of influenza in unvaccinated children and adults: a meta-regression analysis. BMC Infect Dis 2014;14:670.

100. Mizumoto K, Omori R, Nishiura H. Age specificity of cases and attack rate of novel coronavirus disease (COVID-19). MedRxiv 2020; doi:10.1101/2020.03.09.20033142. [In press].

